MCID: UTR037
MIFTS: 20

Uterine Corpus Sarcoma malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Sarcoma

Aliases & Descriptions for Uterine Corpus Sarcoma:

Name: Uterine Corpus Sarcoma 12 14 69
Sarcoma of Corpus Uteri 12
Sarcoma of Uterus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5165
NCIt 47 C6339
SNOMED-CT 64 254877001
UMLS 69 C0338113

Summaries for Uterine Corpus Sarcoma

Disease Ontology : 12 An uterine corpus cancer that is located in the muscles of the uterus or located in other tissues that support the uterus.

MalaCards based summary : Uterine Corpus Sarcoma, also known as sarcoma of corpus uteri, is related to uterus leiomyosarcoma and uterine sarcoma. An important gene associated with Uterine Corpus Sarcoma is SMUG1 (Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1). The drugs Cisplatin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include uterus and the muscles of the uterus or.

Related Diseases for Uterine Corpus Sarcoma

Diseases related to Uterine Corpus Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 uterus leiomyosarcoma 11.0
2 uterine sarcoma 11.0
3 uterine carcinosarcoma 10.9
4 sarcoma 9.9
5 endometrial stromal sarcoma 9.9

Graphical network of the top 20 diseases related to Uterine Corpus Sarcoma:



Diseases related to Uterine Corpus Sarcoma

Symptoms & Phenotypes for Uterine Corpus Sarcoma

Drugs & Therapeutics for Uterine Corpus Sarcoma

Drugs for Uterine Corpus Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
5
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
6
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
7
Busulfan Approved, Investigational Phase 3 55-98-1 2478
8
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
9
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
10
Melphalan Approved Phase 3 148-82-3 4053 460612
11
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
12
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
13
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
14
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
15
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
16
Mesna Approved Phase 3,Phase 1 3375-50-6 598
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
19
Morphine Approved, Investigational Phase 3 57-27-2 5288826
20 Sodium thiosulfate Approved Phase 3
21
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
22
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
23
Irinotecan Approved, Investigational Phase 3,Phase 2 97682-44-5, 100286-90-6 60838
24
Methotrexate Approved Phase 3,Phase 1 1959-05-2, 59-05-2 126941
25
Asparaginase Approved Phase 3 9015-68-3
26
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
27
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
28
Daunorubicin Approved Phase 3 20830-81-3 30323
29
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
30
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
31
Cyproheptadine Approved Phase 3 129-03-3 2913
32
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
34
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
35
Nicotinamide Approved, Nutraceutical Phase 3,Phase 2 98-92-0 936
36
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
37
Dehydroepiandrosterone Approved, Nutraceutical Phase 3 53-43-0 9860744
38
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
39
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
40
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
41 Alkylating Agents Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
43 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
45 Isophosphamide mustard Phase 3,Phase 2,Phase 1
46 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
47 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
48 Antimitotic Agents Phase 3,Phase 2,Phase 1
49 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
50 Anti-Infective Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 157)
id Name Status NCT ID Phase
1 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
3 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
4 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3
5 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
6 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
7 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
8 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3
9 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Completed NCT01012297 Phase 3
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
12 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
13 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
14 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
15 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
16 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3
17 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Recruiting NCT01533207 Phase 3
18 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
19 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Recruiting NCT02306161 Phase 3
20 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT01371981 Phase 3
21 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3
22 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3
23 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Active, not recruiting NCT00354744 Phase 3
24 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Active, not recruiting NCT00354835 Phase 3
25 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Active, not recruiting NCT00134030 Phase 3
26 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Active, not recruiting NCT00075582 Phase 3
27 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
28 Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers Unknown status NCT02052128 Phase 1, Phase 2
29 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2
30 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
31 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
32 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
33 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2
34 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2
35 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2
36 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2
37 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2
38 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2
39 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2
40 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2
41 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2
42 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2
43 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2
44 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2
45 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2
46 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2
47 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
48 Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00003778 Phase 2
49 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2
50 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Completed NCT01553539 Phase 2

Search NIH Clinical Center for Uterine Corpus Sarcoma

Genetic Tests for Uterine Corpus Sarcoma

Anatomical Context for Uterine Corpus Sarcoma

MalaCards organs/tissues related to Uterine Corpus Sarcoma:

39
Uterus

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Corpus Sarcoma:

18
The Muscles Of The Uterus Or

Publications for Uterine Corpus Sarcoma

Variations for Uterine Corpus Sarcoma

Expression for Uterine Corpus Sarcoma

Search GEO for disease gene expression data for Uterine Corpus Sarcoma.

Pathways for Uterine Corpus Sarcoma

GO Terms for Uterine Corpus Sarcoma

Sources for Uterine Corpus Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....